Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Total Current Liabilities (2016 - 2025)

Sanofi's Total Current Liabilities history spans 11 years, with the latest figure at $33.0 billion for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 5.88% year-over-year to $33.0 billion; the TTM value through Dec 2025 reached $33.0 billion, up 5.88%, while the annual FY2025 figure was $32.0 billion, 1.46% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $33.0 billion at Sanofi, up from $31.2 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $33.0 billion in Q4 2025 and bottomed at $24.4 billion in Q4 2021.
  • The 5-year median for Total Current Liabilities is $26.0 billion (2023), against an average of $27.8 billion.
  • The largest annual shift saw Total Current Liabilities rose 0.4% in 2022 before it increased 19.71% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $24.4 billion in 2021, then grew by 0.4% to $24.5 billion in 2022, then rose by 6.43% to $26.0 billion in 2023, then rose by 19.71% to $31.2 billion in 2024, then grew by 5.88% to $33.0 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Total Current Liabilities are $33.0 billion (Q4 2025), $31.2 billion (Q4 2024), and $26.0 billion (Q4 2023).